Full text is available at the source.
Abstract
Daily co-administration of retatrutide and cagrilintide in diet-induced obese male rats produces dose-dependent reductions in body weight and food intake exceeding other treatments.
- Combination therapy leads to superior body weight reduction compared to individual treatments and existing combinations.
- Improvements are observed in metabolic health markers, including cholesterol, triglycerides, and insulin levels.
- The enhanced weight loss is not solely due to reduced food intake, indicating additional drug-specific effects.
- Profiling of plasma proteins reveals an increase in bioenergetic processes associated with the combination therapy.
- Brain analysis identifies overlapping neuronal programs that contribute to energy balance regulation.
Simplified